More importantly, a phase III clinical trial was conducted in NSCLC patients at stage IIIB/IV NSCLC after completing first-line chemotherapy to evaluate overall survival, safety, immunogenicity, and EGF concentration in serum after the CIMAvax-EGF vaccine. Here, EGF is linked to non-small cell lung carcinoma.